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ABSTRACT
This paper provides estimates of the economic impact of non-communicable diseases (NCDs) in China
and India for the period 2012-2030. Our estimates are derived using WHO’s EPIC model of economic
growth, which focuses on the negative effects of NCDs on labor supply and capital accumulation.
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diabetes, and mental health). Our undiscounted estimates indicate that the cost of the five main NCDs
will total USD 27.8 trillion for China and USD 6.2 trillion for India (in 2010 USD). For both countries,
the most costly domains are cardiovascular disease and mental health, followed by respiratory disease.
Our analyses also reveal that the costs are much larger in China than in India mainly because of China’s
higher income and older population. Rough calculations also indicate that WHO’s Best Buys for addressing
the challenge of NCDs are highly cost-beneficial.
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1. Introduction 
Previous research has documented the impact of non-communicable diseases (NCDs) 
worldwide, in terms of avoidable deaths (Marrero, Bloom, & Adashi, 2012), disability (Murray, 
et al., 2012a, 2012b; Salomon, et al., 2012), and economic impact (Abegunde, Mathers, Adam, 
Ortegon, & Strong, 2007; Bloom et al., 2011b, 2011c). Studies have highlighted the potential 
increase in chronic disease in developing and emerging nations and the overall impact on 
population health that this could have (Kearney et al., 2005). In fact, NCDs are responsible for 
65.5 percent of all mortality (Lozano et al., 2012), and account for 54 percent of healthy life 
years lost, as measured by Disability-Adjusted Life Years (DALYs) (Murray et al., 2012b). 
Differentials in health-related behaviors and outcomes represent an important component of 
disparities between the well-being of populations, both across countries and over time (Becker, 
Philipson, & Soares, 2005). A comparison of India and China offers a good example. The 
economies of both countries have undergone significant changes in terms of demographic and 
economic structure (Bloom et al., 2010); however, recent estimates suggest that health and 
disability may represent significant impediments to further growth, but with different outcomes 
for the two countries. 
The global burden of non-communicable diseases is expected to increase as a result of two 
related demographic phenomena (Bloom, et al., 2011a, 2011b), first the rise in global population, 
and second the growth of the older population. This is particularly the case for certain emerging 
nations, such as China and India. Currently 5.3 percent of India’s population and 8.6 percent of 
China’s is aged 65 or older; however, this will increase to 10.2 percent and 21 percent, 
respectively, by 2035 (Wolf et al., 2011). This has important implications for the burden of 
disease because this age group is the most affected by illness (Bloom et al., 2011b; Dey et al., 
2012; Williams & Krakauer, 2011; National Sample Survey Organisation, 2006). These trends 
have particularly important implications for emerging nations, which rely on rapid economic 
transformation to reduce poverty and improve population welfare.  
Disease burden can impact economic growth through a number of different pathways. For 
example, poor health is associated with early retirement (Dwyer & Mitchell, 1999), negative 
expectations regarding employment (McGarry, 2004), and reduced productivity (Lopez-
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Casasnovas, Rivera, & Currais, 2005). These factors may contribute to lowering labor supply 
and increasing the ratio of dependents to workers. 
By increasing public health expenditures to treat NCDs and reducing the amount of household 
taxable income by pushing ill people out of the workforce, NCDs may reduce the net availability 
of government resources. As a result, this limited fiscal capacity could compel governments to 
increase tax rates to meet rising health expenditures, which in turn would depress aggregate 
demand, further limiting the growth potential of the economy and reducing the public sector’s 
ability to invest in strategic areas. Increased health expenditures would impede the accumulation 
of physical and human capital (i.e., the portion that arises from better education). In addition, the 
types of conditions that affect the health of aging populations may require an ever-growing share 
of resources, thus reducing a government’s ability to target poverty reduction or improvements in 
education. 
Existing empirical research has established a strong relationship between economic growth and 
health, including in China and India (Bloom et al., 2010), reflecting causality running from 
health to economic growth (Bloom, Canning, & Sevilla, 2004 & Bloom, Canning, & Fink, in 
press), as well as from the longer-understood effect of economic growth on improved health. 
One way of estimating the magnitude of the impact of health on economic growth is to construct 
a macroeconomic model that incorporates health alongside the factors of production. Growth 
models have a long history in economics, dating back to Solow (1956), who described the 
process of economic growth as a function of the aggregates of capital and labor. In this paper we 
adopt the approach in Abegunde and Stanciole (2006), and Bloom et al. (2011b), and allow for 
an effect of health on national income in two respects. First, NCDs cause the diversion of savings 
from capital investment into non-productive health care, and second, NCD mortality results in 
the reduction of the stock of available labor supply. 
We present and compare results associated with the burden of disease using this EPIC model 
from China and India over the time period 2012-2030. We assess the economic impact of four 
types of NCDs (cardiovascular disease, cancer, chronic respiratory disease, and diabetes), and 
also include estimates of the effect of mental health. We describe the relative contribution of 
each to the total and identify the most important of these in terms of overall magnitude. These 
results allow us to assess the potential impact of NCDs on each economy over the next 18 years. 
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The rest of this paper is structured as follows. Section 2 supplies background on the nature and 
magnitude of NCDs and their risk factors in general as well as in China and India specifically. 
Section 3 describes the model and data used in the analysis, specifically WHO’s EPIC model. 
Section 4 presents results from China and India, Section 5 discusses the results, and Section 6 
provides conclusions and offers suggestions for further research. 
2. Background on NCDs, their prevalence in China and India, and relevant policy 
implications 
The transition from infectious disease to NCDs as the dominant cause of mortality is usually 
regarded as a result of successful infectious disease control and greater longevity. However, the 
first of these claims cannot yet be made for India. As shown in Figure 1, the burden of infectious 
disease remains high in India, with communicable, maternal, perinatal, and nutritional conditions 
accounting for 37 percent of all mortality, compared with just 7 percent in China. While China 
has made good progress with regard to successful infectious disease control, India continues to 
face a double burden of disease. 
Figure 1. Proportion of mortality due to NCDs and other causes in China and India 
 
 
Source: World Health Organization, 2011c 
Figure 2 casts some doubt on the strength of the second claim – that greater longevity accounts 
in part for the new dominance of NCDs as a cause of death – by showing that both China and 
India experience a substantial burden of premature NCD deaths. Around 60 percent of NCD 
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deaths in India and 35 percent in China involve people under the age of 70, in contrast to fewer 
than 30 percent in much of Western Europe.  
Figure 2. Percentage of all NCD deaths occurring under age of 70:  
Male (left) and Female (right)
a
 
 
 
a.
Exact values: Male – India 61.8, China 43.9; Female – India 55.0, China 32.0;  
 Source: World Health Organization, 2011d. 
 
The development and progression of NCDs is determined by both modifiable and non-
modifiable risk factors. Non-modifiable risk factors include age, sex, and genetic make-up. 
Although these risk factors cannot be the primary targets of interventions, they are important to 
consider as they influence the overall burden of disease. Nearly all NCDs increase in prevalence 
with age (Dey et al., 2012; Williams & Krakauer, 2011; Zhao, 2013). Due to rapid population 
aging alone, both China and India will be at increased risk for non-communicable diseases if 
other risk factors remain reasonably constant.  
However, population aging is not the only risk factor that is driving China and India toward an 
increased burden of NCDs and NCD-related premature mortality. The prevalence of modifiable 
NCD risk factors, such as tobacco use, harmful alcohol use, poor diet, and sedentary lifestyles 
has risen steadily over the past 30 years in both countries. These behavioral trends are related to 
much larger changes in society: increased income, urbanization, and the transition to occupations 
requiring less physical activity. In the context of China and India, air pollution — both indoor 
and outdoor — is also an important risk factor due to its role in cancer, chronic lung disease, and 
cardiovascular disease (Institute for Health Metrics and Evaluation, 2013a, 2013b). 
See Table 1 for a comparison of major NCD risk factors. Overall, India fares better than China in 
terms of modifiable NCD risk factors, with a lower prevalence of risk behaviors such as smoking 
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and physical inactivity as well as a lower prevalence of biomarkers for disease such as raised 
blood pressure and raised cholesterol.  
Table 1. Percentage of population with specific NCD risk factors in India and China 
 
Risk factors 
India China 
Men Women Total Men Women Total 
Daily tobacco smoking 25.1 2.0 13.9 49.3 2.1 26.3 
Overweight (BMI>25kg/m
2
) 9.9 12.2 11.0 25.5 25.4 25.4 
Obese (BMI>30kg/m
2
) 1.3 2.4 1.9 4.7 6.7 5.7 
Physical inactivity 10.8 17.3 14.0 29.3 32.0 30.6 
Raised cholesterol 25.8 28.3 27.1 31.8 35.3 33.5 
Raised blood glucose 10.0 10.0 10.0 9.5 9.3 9.4 
Harmful use of alcohol 3.5 0.4 2.0 6.9 0.2 3.8 
Raised blood pressure 33.2 31.7 32.5 40.1 36.2 38.2 
Source: World Health Organization, 2011a, 2011c 
 
Daily tobacco smoking is a major risk factor for which both China and India can improve. China 
is the world’s largest producer and consumer of tobacco. Liu et al. (1998) note that cigarette 
smoking among Chinese men rose rapidly in the period 1952-1996 and has since stabilized. 
However, since there is a lag of several decades between the initiation of smoking and smoking-
related morbidity and mortality, the full health implications of the previous increases in smoking 
have not yet been observed. Roughly 10 percent of the world’s smokers are in India, which is the 
second largest group of smokers in the world, after only China. In India, beedi smoking (also 
spelled bidi or biri) is common, and accounts for about half of Indian tobacco consumption. 
Beedies are filterless Indian cigarettes that consist of tobacco rolled in a tendu or temburni leaf 
and may be flavored. While beedies are seen as a low-cost alternative to cigarettes, they may be 
more harmful than conventional cigarettes, because they deliver more nicotine, carbon 
monoxide, and tar (Centers for Disease Control and Prevention, 2013; Ministry of Health and 
Family Welfare, 2008). Taxes on cigarettes are low and typically do not apply to beedies due to 
the fact that their sale is poorly regulated (John et al., 2010). Indians consume tobacco in other 
forms, as well, including gutka and pan masala (types of chewing tobacco). Data from the third 
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wave of India’s National Family Healthy Survey show that among individuals aged 15-49, 57 
percent of men and 11 percent of women use tobacco in some form (International Institute for 
Population Sciences, 2007; Parasuraman et al., 2009). 
The prevalence of overweight (see Figure 3) is higher in China than India and continues to rise in 
both countries. Asians are at risk for diabetes at lower BMIs than Caucasians. Measures of 
central adiposity, such as waist/hip ratio, are therefore preferred to BMI for South Asia (Dudeja 
et al., 2001), but these data are not available on a national level. 
Figure 3. Prevalence of overweight, ages 20+, age-standardized: 
Male (left) and Female (right) 
 
Source: World Health Organization, 2011b 
Though a thorough review of the nutrition transition in China and India is beyond the scope of 
this paper, it is important to note that changes in diet can have an independent effect on NCD 
risk, in addition to changing BMI. Popkin et al. (2001) note that in both China and India, dietary 
changes have heightened NCD risk, with an increase in meat consumption and edible oils in 
China, and increased dairy and added sugar in India. 
Having reviewed the major risk factors, we can now consider different NCDs as causes of 
mortality. As shown in Figure 1, NCDs account for a greater proportion of overall mortality in 
China than India: 83 percent and 53 percent, respectively. Furthermore, absolute NCD mortality 
is greater in China than it is in India; NCDs caused an estimated 8 million deaths in China in 
2008, and 5 million deaths in India (World Health Organization, 2011b). However, it is 
important to note that this is largely due to differences in age structure. China currently has an 
older population than India, and age itself is a risk factor for NCDs. As shown in Figure 4, India 
actually has a slightly higher age-standardized death rate than China for NCDs overall. This is 
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due to the greater prevalence of ischemic heart disease in India, as compared with China (see 
Figure 5). 
 
Figure 4. NCDs: broad causes of mortality, age-standardized rates 
 
Source: World Health Organization, 2008. 
Figure 5 shows specific diseases of interest, either because they are large contributors to overall 
NCD mortality, or because prevalence was markedly different in China and India. The overall 
age-standardized mortality attributable to cardiovascular disease is moderately higher for India 
than China, but there is variation within this category, with India having much higher mortality 
from ischemic heart disease – commonly called a “heart attack” – and China having higher 
mortality for cerebrovascular disease, or stroke.  
0 200 400 600 800 
All NCDs 
Cancer 
Cardiovascular diseases 
Respiratory diseases 
India China 
(Deaths per 100,000) 
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Figure 5. NCD-specific causes of mortality, age-standardized rates 
 
Source: World Health Organization, 2008. 
China has substantially higher age-standardized mortality from cancer overall, with particularly 
elevated rates of death from cancers of the esophagus, stomach, colon and rectum, liver, and 
trachea, bronchus, and lung. These outcomes are associated with smoking, outdoor air pollution, 
a diet low in fruits and high in sodium (stomach cancer), and low physical activity (colon and 
rectum cancers). India fares worse than China when it comes to mortality due to female cancers. 
The age-standardized mortality rates from breast and cervical cancer are approximately three 
times higher in India than in China (Ferlay et al., 2013).
1
 
In light of the large and growing health burdens of NCDs in China and India, we review some 
NCD-related policies and their potential health implications. Table 2 shows some of the WHO 
“best buys”—a set of interventions designed to reduce NCD mortality and morbidity, and 
identified as being highly cost-effective and feasible to implement given the constraints of many 
low- and middle-income country health systems (Bloom et al., 2011b, 2011c; World Health 
Organization, 2011b). The first three sets of interventions address risk factors and the final two 
                                                          
1
 Age-standardized mortality rates for breast cancer and cervical cancer are 5.7 and 4.3 per 100,000 population in 
China and 11.1 and 15.2 per 100,000 population in India, respectively.  
0 50 100 150 200 250 
Esophagus cancer 
Stomach cancer 
Liver cancer 
Trachea, bronchus, lung cancers 
Alzheimer and other dementias 
Hypertensive heart disease 
Ischaemic heart disease 
Cerebrovascular disease 
COPD 
Diabetes mellitus 
India China 
(Deaths per 100,000) 
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sets focus on the medical management of NCDs. Here we discuss China and India’s current 
policies on tobacco control and cardiovascular disease therapy, since these are the most effective 
of the identified best buys in terms of preventing avoidable deaths. 
Table2: “Best Buy” interventions for reducing NCDs 
 
There has been mixed progress on tobacco control in China. Ma et al. (2010) explain that some 
local governments have implemented smoking bans in public places, such as hospitals, schools, 
and public transportation, but that compliance remains low. China increased the excise tax on 
tobacco products in 2009, but Gao, Zheng, and Hu (2012) find that because the Chinese State 
Tobacco Monopoly Administration (STMA) determines prices, this tax increase has not raised 
retail prices or decreased tobacco consumption, as has occurred in many market economies that 
adopted higher excise taxes on tobacco. Although there is a ban on tobacco advertising on 
television, radio, and in newspapers, there is not currently a restriction on other sponsorship 
activities. Tobacco sponsorship and advertising in schools and libraries therefore remains 
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strong.
2
 While China’s cigarette packages are required to provide a general warning that smoking 
is harmful for health, these warnings are small and ineffective and do not provide specific 
information or images about the health risks of smoking. Wan et al. (2012) suggest that conflict 
of interest, where the STMA is both the tobacco industry and its regulator, prevents effective 
implementation of tobacco control measures.  
There is a similar situation with regard to tobacco control in India. India signed and ratified the 
global Framework Convention on Tobacco Control, but compliance in terms of smoking bans in 
public places and restrictions on advertisements remains poor (Goel, Ravindra, Singh, & Sharma, 
2013; John, et al. 2010). There has been some recent progress; for example, in April 2013, the 
Government of India enacted “The Cigarettes and Other Tobacco Products (Prohibition of 
Advertisement and Regulation of Trade and Commerce, Production, Supply and Distribution) 
Act, 2003” (COTPA 2003), which requires all tobacco products to carry pictorial health 
warnings (Press Information Bureau, 2013). In June 2013, Karnataka became the 26
th
 Indian 
state to ban the manufacture and sale of tobacco-containing gutka and pan masala (Express News 
Service, 2013).  
Another major policy challenge is improving medical management of chronic conditions. This is 
also known as secondary prevention (i.e., methods to diagnose and treat existing disease before it 
causes significant morbidity). A major barrier to secondary prevention is the poor availability of 
NCD medicines in low- and middle-income countries, including China and India (van Mourik, 
Cameron, Ewen, & Laing, 2010; Mendis, 2007). Many times, basic medications such as insulin 
to manage diabetes, antihypertensive drugs, or aspirin for heart attack fatality reduction, which 
can hugely impact the course of NCDs, are not available from local pharmacies, or are only 
available at a prohibitive price. Health systems can fail at many points: surveillance, diagnosis, 
access to medicines, and patient adherence (Gu et al., 2002). China and India have the potential 
to improve access to NCD medications, with a growing healthcare workforce and a growing 
pharmaceutical industry. India has recently taken steps to improve access to essential medicines. 
The Government of India announced that it will implement a price ceiling on all drugs on the 
national essential medicines list and, as part of its goal to increase public healthcare spending, 
                                                          
2For more information on tobacco’s role in sponsoring schools, see: http://www.bloomberg.com/news/2011-09-
20/china-endorsing-tobacco-in-schools-adds-to-10-trillion-gdp-cost.html 
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will provide these drugs for free to government-run hospitals and clinics in a 75%-25% cost-
sharing arrangement with the states (Baja, 2012; Singha, 2012). Following the example of Tamil 
Nadu, a central procurement agency will be developed, and the government expects generic 
manufacturers to supply the drugs.  
Furthermore, China and India will need to build infrastructure to deal with the aging population. 
While recent research suggests that China’s efforts to expand insurance coverage have reached a 
substantial proportion of the over-45 age group, further action is needed to fully cover these 
individuals and protect them from impoverishing out-of-pocket spending (Strauss et al., 2012). 
Research from India cites low levels of access to insurance for the older population and a great 
need for building up the capacity to deliver geriatric care across the country (Dey et al., 2012; 
Evans et al., 2011).  
3. Model and data  
Several modeling approaches have been used to estimate the aggregate economic impact of 
disease (World Health Organization, 2009). A common methodology is the cost-of-illness or 
human capital approach, which combines 'direct costs' (medical care, travel costs, etc.) and 
'indirect costs' (the value of lost production because of reduced working time) into an overall 
estimate of economic impact on society, often expressed as a percentage of current GDP. 
Although the cost-of-illness approach focuses on the societal impact of disease or injury, it 
provides only a partial picture of the true macroeconomic impact of disease, and fails to consider 
the contribution of depleted capital accumulation, investment in human capital, and demographic 
change to diminished economic growth. 
Another popular alternative is the use of the value of statistical life (VSL) approach. This 
approach is based on the application of willingness-to-pay methods to estimate the overall 
welfare impact of disease, including both market and non-market effects. VSL models can be 
seen to complement cost-of-illness estimates as they incorporate a more comprehensive measure 
of the benefits of living in good health, which includes the value of non-market production and 
consumption, non-labor income, leisure time, and any premiums attached to the avoidance of 
pain and suffering. Nonetheless, a number of important restrictions limit the applicability of VSL 
models, particularly in the case of NCDs, including that: (a) the key parameter (the VSL itself) is 
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not observable and subject to extensive debate; (b) the methodology is more readily applicable to 
mortality as opposed to morbidity impacts; and (c) the economic impact estimates are not 
bounded and can generate extreme results with difficult interpretation. 
An augmented Solow model, which assumes that national income depends on the capital stock, 
the labor force size, and aggregate measures of human capital, is the basis for the WHO EPIC 
model applied in this paper. EPIC treats health, as indicated by NCD prevalence, as a central 
component of human capital, relying on estimates of the impact of NCDs from microeconomic 
studies and using them to calibrate the size of the effects at the aggregate level (Bloom & 
Canning, 2008). This approach is very flexible and suitable for applications with limited data 
availability. Moreover, since it is based on structural production functions it avoids many of the 
issues that affect other empirical models of economic growth. The results can also be used to 
decompose the differences in GDP across countries into input factors as implied by the aggregate 
production function. 
3.1. Pathways for the impact of NCDs on GDP  
Dynamic macroeconomic models usually represent the economy as a system of complex 
interactions between three main types of agents: households, firms, and the government, where 
the last is often omitted for the sake of analytical tractability and a clearer exposition. Economic 
growth depends on the key production factors, capital, labor, and technology, that affect the flow 
of income between the agents within the system. If injections of these production factors are 
greater (or conversely, smaller) than leakages like depreciation, then total output increases (or 
decreases). In the equilibrium of a simple closed economy model without government, aggregate 
income of all economic agents is equal to aggregate expenditure plus aggregate savings. 
In such a framework, NCDs affect economic growth through three main channels (World Health 
Organization, 2009). First, NCDs can increase health expenditures for all three types of agents. 
For households, NCD treatment and care expenses can force them to reduce consumption of non-
health items as well as savings and investment. This is especially the case in developing 
countries with limited systems of health coverage and where household consumption is often 
quite close to subsistence level. For firms, NCDs can affect the amount of available income, 
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given the need to pay for premiums and social insurance contributions to protect the wellbeing of 
their workers.  
The second channel of NCDs’ macroeconomic impact operates through labor and productivity 
losses. The direct labor supply impact reduces the number of working-age individuals, due to 
both increased mortality and reduced on-the-job productivity for the sick. If employees die or 
suffer from a disease that reduces their productivity, then their corresponding contribution to 
total output is lost for the economy. By contrast, if people who do not work (retirees, children, 
etc.) suffer from the same illnesses, total output stays unaffected.
3
 Therefore it is important to 
know the extent to which employees are differentially affected by the corresponding illnesses. 
Indirect productivity impacts can take the form of reduced cognitive abilities and increased 
absenteeism and worker turnover. Both direct and indirect impacts can also lead to ripple effects, 
such as reduced household earnings and firms’ reluctance to invest in workers’ training and 
capacity development, which can in turn further hinder economic growth. 
Finally, NCDs affect the incentives for savings and for investment in both physical and human 
capital. NCDs can force people into early retirement, therefore reducing overall labor market 
participation and increasing the ratio of dependents to workers. The individuals forced into early 
retirement often require special medical care and specialized services, which reduce the amount 
of resources that can be employed in productive activities and exert cost pressures on those firms 
that provide retiree health care or health insurance. People leaving the workforce must be 
replaced by new workers, which raises firms’ hiring and training costs. Furthermore, the 
expectation of shorter post-retirement life expectancy can lead to lower savings during active 
life, which in turn contributes to reducing the stock of physical capital per worker. A related 
effect reduces incentives to invest in training, education, and other forms of human capital due to 
shorter payoff periods in the labor market. 
3.2. EPIC model structure, operation, and key parameters 
The modern macroeconomic literature on growth began with Solow (1956), who provides a 
framework for considering the growth path of national income as explained by physical capital 
accumulation and exogenously given technological progress. The model was the first to explain 
                                                          
3
 Simple accounting shows the following: when an employee dies, per capita GDP shrinks, whereas when a retiree 
dies, per capita GDP rises. However, we do not make any statements about per capita GDP.  
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convergence, that is, the empirical regularity that, among countries that share similar structural 
characteristics (institutions, preferences, etc.), those that are poorer tend to grow faster (c.f. 
Kaldor, 1957; Barro & Sala-i-Martin, 1992). The crucial mechanism is the following: in poor 
countries the capital stock is low and consequently the marginal product of capital is high. 
Therefore, capital accumulation contributes substantially to economic prosperity in earlier stages 
of development and during the transition towards being an industrialized, knowledge-based, 
modern economy.
4
 In developed countries, by contrast, the physical capital stock is already large 
and its marginal product is therefore low. Physical capital accumulation is thus not the main 
driving force of growth in this situation. This role is rather assumed by technological progress, 
which was first endogenously explained within a general equilibrium framework by the seminal 
contributions of Romer (1990), Grossman and Helpman (1991), and Aghion and Howitt (1992).
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Jones (2002) and Keller (2009) emphasize that the G-7 countries were responsible for 84 percent 
of worldwide R&D spending in 1995. It is therefore most likely that the research frontier is 
pushed forward by these countries, and knowledge diffuses from them to poorer ones that did not 
spend that much on R&D in the past. When modeling the impact of non-communicable diseases 
in China and India, we therefore assume that technological progress is exogenous and mainly 
focus on its influence on the working-age population and physical capital accumulation. 
Following Solow (1956), aggregate output in country   at time   is given by 
             
     
    
where   is an exogenously evolving productivity parameter measuring efficiency in production, 
that is, the technological level of country   at time  ,   is the aggregate physical capital stock 
(i.e., it represents all the machines and buildings used in the production process),   is the stock of 
labor in the economy (i.e., it represents all individuals supplying their skills on the labor 
market),and   denotes the elasticity of final output with respect to capital. The productivity 
parameter   and the elasticity of final output with respect to capital,   alpha, are both 
independent of NCDs. The former grows at an exogenously given rate. 
                                                          
4
 For a discussion of convergence dynamics, see McQuinn and Whelan, 2007. 
5
 These endogenous growth models were refined in the next two decades by e.g. Jones (1995), Segerstrom (1998), 
Peretto (1998), Howitt (1999) and Strulik (2005). 
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Various extensions have been proposed, such as endogenizing technology (Romer, 1990), and 
the addition of human capital (Mankiw, Romer, & Weil, 1993). We adopt the EPIC model 
developed in Abegunde and Stanciole (2006), and Bloom et al. (2011b). This augments the 
Solow model by allowing health to impact economic growth via the two paths described above, 
namely the accumulation of physical capital and the supply of labor.
6
 
3.2.1. Capital accumulation 
First, health care spending diverts resources from productive investment in capital. The 
aggregate physical capital stock in an economy can then be written as 
                              
where   represents the savings rate (i.e., the fraction of final output invested in the creation of 
new capital),   represents the treatment costs of the disease,   is the fraction of these costs 
financed out of an individual’s savings, and   is the rate of depreciation. This equation describes 
the evolution of the aggregate capital stock, which positively depends on the savings rate and 
negatively depends on the costs of curing the illness under consideration as well as on the 
fraction of these costs paid out of savings. 
3.2.2. Evolution of the supply of labor  
Second, labor supply is affected by age-specific disease mortality, so higher prevalence is 
associated with reductions in the numbers of workers in a particular cohort. The evolution of the 
labor force is given by the equation 
             
      
 
   
    
                     
  
  
              
 
where   refers to age,   
  represents the cohort specific mortality rate of individuals at age  ,   
  
is the cohort size of individuals at age  ,         represents the birth rate at time       and   is 
the retirement age. Note that it is assumed that only individuals who are older than 15 years 
actively participate in the labor market. The first term of this equation represents the evolution of 
                                                          
6
 The term “physical” is used to distinguish it from human capital. There is no “financial” capital in the Solow-EPIC 
model because it is assumed that capital is the only savings vehicle and there is efficient and immediate allocation of 
household savings toward their most productive uses. 
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the workforce for all persons who belonged to it in the previous time period and the second term 
represents the cohort size of the young who are entering the workforce at time  . The term in the 
product adjusts for deaths of children and adolescents up to the age of 15 when the young enter 
the labor market. NCD-related mortality enters the cohort-specific death rates and therefore 
exerts its impact on the economy via this second channel. The magnitude of this effect will 
depend on the structure of mortality rates. The greater the extent to which employees are 
differentially affected, the more adverse the consequences for GDP per capita (see discussion in 
section 3.1). 
We assume that the world technology frontier grows by 1 percent every year. Consequently, for 
given capital and labor input, the next year’s output will be higher by 1 percent.7 The level of the 
technology parameter has been obtained by calibrating the predicted output of the model for 
given capital and labor inputs to the actual output in the corresponding country.  
The use of an economically founded and accepted framework to assess the macroeconomic 
impact of non-communicable diseases has some advantages as compared with other standard 
techniques like the cost-of-illness approach (see Currie, Dymond Kerfoot, Donaldson, & 
Macarthur, 2000; Rice, 2000 for its advantages and disadvantages) or the estimation and 
aggregation of the value of a statistical life – VSL (Viscusi & Aldy, 2003). First, it takes into 
account the adjustment mechanisms and dynamics by which economies are characterized. For 
example, if people die because of a certain disease, this does not lead to a one-for-one drop in 
output as the cost-of-illness approach and the VSL approach assume. The reason is that other 
workers (coming either from the pool of unemployed people or from other jobs) and/or capital 
can be used to substitute for the loss of labor, at least up to a certain extent. Furthermore, as the 
Solow (1956) model is dynamic in nature, the economic impact of diseases can easily be traced 
over time, once the mortality patterns as well as the effects of treatment costs on savings are 
known. Finally, as compared with the VSL approach, the simulation of the Solow (1956) model 
                                                          
7
 The EPIC model abstracts from the barriers to technology adoption and diffusion. The model assumes that there is 
immediate diffusion of new technology (i.e., the parameter A in China grows by the same absolute amount as it 
grows in the rest of the world), while the level differences in the parameter persist indefinitely.  
17 
abstracts from subjective costs and feelings regarding death and thus allows for focus solely on 
the economic dimension.
8
 
 
3.3. Data sources 
The estimates are based on WHO projections of the mortality trajectory associated with these 
five conditions, as well as on WHO estimates of labor force participation rates and imputed rates 
of technological progress constructed as part of this project.  
Data on economic variables were obtained from Abegunde and Stanciole (2006), the World 
Development Indicators & Global Development Finance database, the IMF’s Global Economic 
Outlook database, and the Penn World Tables. Demographic and health variables were obtained 
from UN data on population, and the Global Burden of Disease (GBD) database of WHO. 
Results are presented for five conditions in the model (ischemic heart disease, cerebrovascular 
disease, diabetes, chronic obstructive pulmonary disease (COPD), and breast cancer), which are 
then scaled up using WHO data on DALYs to reflect the four NCDs that are the focus of the UN 
(cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes). The scaling is 
implemented by calculating the proportion of DALYs in a particular domain (e.g., cancer) that 
are accounted for by the relevant disease in EPIC (breast cancer in this instance). If breast cancer 
accounts for 10 percent of the total DALYs lost to cancer, the scaling factor applied to the EPIC 
results for breast cancer to obtain a result for all cancers is 0.1. Scaling factors are calculated for 
each country. Similarly, we use WHO data on mental illness DALYs to include estimates of 
economic losses from mental health conditions. The mental health scaling factor is calculated by 
obtaining the ratio of DALYs accounted for by the four NCD domains to DALYs accounted for 
by mental health conditions. 
                                                          
8
 The transitional dynamics of the Solow (1956) model and its steady-state properties carry over to the EPIC 
framework. The only difference from the standard Solow (1956) model is that the savings rate and the population 
growth rate are now time-varying because they depend on the prevalence of the diseases under consideration. The 
standard diagram used to characterize the dynamics of the capital stock per unit of effective labor in the Solow 
(1956) model can be applied with the feature in mind that the curves describing savings on the one hand and 
depreciation and dilution of capital on the other would not be fixed but move according to the impact of the 
analyzed NCDs. 
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4. Results  
This section presents results from the EPIC model for China and India and the results we find by 
scaling up to disease categories of the five NCD domains. We examine the time period 2012-
2030 for each country and estimate the cumulative lost economic output from diabetes, 
cardiovascular diseases, chronic respiratory diseases, cancers, and mental health. We then 
compare the estimated losses for the two countries. Results are presented on a disease- and 
country-specific basis in 2010 USD.  
4.1. China 
Table 3 presents the raw output from the EPIC model for China. The EPIC model evaluates the 
output losses from five specific diseases for the period 2012-2030, namely diabetes, ischemic 
heart disease, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), and 
breast cancer. The results are shown in 2010 USD. Of the individual diseases, cerebrovascular 
disease is the most costly, associated with a loss of almost 2010 USD 4.7 trillion. This is 
followed closely by COPD at 2010 USD 4.0 trillion. The total (undiscounted) loss associated 
with these illnesses is USD 11.0 trillion over the whole period.
9
 
Table 3.Output losses, 2012-2030, model raw output for China 
Disease Loss, 2010 USD 
(trillions) 
Diabetes 0.49 
Ischemic heart disease 1.63 
Cerebrovascular disease 4.66 
COPD 4.03 
Breast cancer 0.19 
TOTAL 11.0 
 
                                                          
9
 This exercise compares the outcomes for an economy under two scenarios, with and without the effect of NCDs, 
and reports the difference in output, summed over a 19-year period. Discounting would affect the amount of the 
losses from NCDs, but not the fact that the losses would still be substantial. Very roughly, using a 3% discount rate, 
the losses reported in the paper would be about 66% as large as those we report.  In the Discussion, where we 
compare the losses to current outlays that could help avert these losses, we address this issue again. 
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Table 4 presents results from scaling up these individual diseases to obtain the estimated impact 
of the five major domains that are the main focus of the recent UN summit on NCDs: diabetes, 
cardiovascular disease, respiratory disease, cancer, and mental health. We use estimates of 
DALYs, which allows us to assess the contribution of each disease in the EPIC model to each of 
these five types of NCD. The scaling factors reflect country-specific estimates from the Global 
Burden of Disease 2004 Update study (World Health Organization, 2008).
10
  
The first column shows each of the five WHO-defined disease domains, while the second shows 
the diseases addressed by the EPIC model. The third shows the raw output for physical illness. 
The contributions of ischemic heart disease and cerebrovascular disease are summed to obtain 
the burden associated with cardiovascular disease. Next, the burdens for the four main NCD 
disease domains are obtained by applying the scaling factors associated with each individual 
NCD in column 4 to the totals in column 3. The final column shows the scaled raw output. 
Finally, the mental health burden is obtained by applying the DALY-derived scaling factor to the 
scaled total of the four physical health conditions. The total losses associated with physical 
disease and mental health are USD 18.4 trillion and USD 9.4 trillion, respectively.  
 
 
  
                                                          
10
 See the Appendix for early estimates of output losses using the 2010 update of GBD. Notably, the 2010 data 
suggest lower losses from mental health than we present in the body of this paper. 
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Table 4. Scaling of EPIC output for 2012-2030 
to match five WHO NCD domains for China 
(trillions of 2010 USD) 
 
WHO Disease EPIC Disease 
EPIC Raw 
Output 
Disease Scaling 
Factor 
Scaled Raw 
Output 
Diabetes Diabetes 0.49 Diabetes/1.00 0.49 
Cardiovascular 
disease 
  
(IHD+CBD)/0.76 8.25 
 Ischemic Heart 
Disease 
1.63 
  
  Cerebrovascular 
Disease 
4.66 
    
Respiratory disease COPD 4.03 COPD/0.71 5.71 
Cancer   Breast cancer/0.05 3.97 
  Breast cancer 0.19     
Total physical       18.41 
Mental health     Total physical * 0.51 9.43 
Overall total       27.84 
 
Figure 6 shows the contribution of each of these domains to the total for the same period. Mental 
health is the largest category, followed by cardiovascular diseases and respiratory disease. The 
economic costs of diabetes are estimated to be relatively small (2 percent), perhaps because 
diabetes leads to other conditions (e.g., cardiovascular disease) that are ultimately recorded as the 
cause of missed work and death. It is important to note that although small relative to the others, 
the absolute losses associated with diabetes and cancer are very high. 
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Figure 6. Contribution of each disease to overall lost output for China 
 
 
 
4.2. India 
Table 5 presents results for the raw output of the EPIC model for India. Ischemic heart disease is 
estimated to be the single most costly NCD, followed by COPD. The total loss associated with 
the five specific diseases is USD 2.6 trillion. 
Table 5.Output losses, 2012-2030, model raw output for India 
Disease Loss, 2010 USD 
(trillions) 
Diabetes 0.15 
Ischemic heart disease 1.21 
Cerebrovascular disease 0.49 
COPD 0.71 
Breast cancer 0.02 
TOTAL 2.58 
 
2% 
30% 
21% 14% 
34% 
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22 
Table 6 shows the results from scaling up each disease in the EPIC model to the five WHO 
categories. The scaling factors reflect results from the Global Burden of Disease 2004 Update 
study on India (World Health Organization, 2008). The total losses associated with physical 
disease and mental health are USD 3.9 trillion and USD 2.3 trillion, respectively. 
 
Table 6. Scaling of EPIC output for 2012-2030 
to match five WHO NCD domains for India 
(trillions of 2010 USD) 
 
WHO Disease EPIC Disease 
EPIC Raw 
Output 
Disease Scaling 
Factor 
Scaled Raw 
Output 
Diabetes Diabetes 0.15 Diabetes/1.00 0.15 
Cardiovascular 
disease 
  
(IHD+CBD)/0.76 2.25 
 Ischemic Heart 
Disease 
1.21 
  
  Cerebrovascular 
Disease 
0.49 
    
Respiratory disease COPD 0.71 COPD/0.61 1.17 
Cancer   Breast cancer/0.08 0.31 
  Breast cancer 0.02     
Total physical       3.87 
Mental health     Total physical * 0.59 2.28 
Overall total       6.15 
 
Figure 7 shows the relative contribution of each disease domain to the total figure. 
Cardiovascular disease is the largest category, closely followed by mental health and then 
respiratory disease. The losses attributable to diabetes and cancer are relatively small in 
comparison.  
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Figure 7. Contribution of each disease to overall lost output for India 
 
4.3. Comparison of China and India 
Figure 8 presents results comparing the estimated losses for each disease in China and India for 
the period 2012-2030. The cost associated with each domain is substantially higher for China 
than India. These disparities arise largely due to the difference in the initial level of GDP in the 
two countries and secondarily to the projected difference in GDP through 2030 (which are based 
on IMF estimates). This is due to the structure of the model, in which reductions in labor supply 
or capital formation are most costly at higher levels of GDP. For a comparison of the economic 
burden of disease in high-, middle-, and low-income countries, see Bloom, et al. (2011b). 
2% 
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Figure 8. Comparison of lost output for China and India, 2012-2030 
 
In both countries, the economic costs of diabetes are estimated to be a very small fraction of the 
total losses from NCDs. However, it is important to note that the absolute losses associated with 
all five of these disease categories are high in both China and India. Furthermore, the values for 
diabetes are understated since it is not typically fatal on its own, but often leads to cardiovascular 
disease and other health problems that carry a high burden of mortality, such as kidney disease. 
5. Discussion 
The results from the EPIC model suggest that the magnitude of the losses associated with non-
communicable diseases is significant for India, and even more so for China. However, these 
figures refer to the economic costs over the course of a 19-year period, and therefore it is 
important to put these numbers in context. Bearing in mind that the estimates made in this report 
are intended to give only a very rough sense of the economic burden, we can compare the 
estimates to the approximate total health expenditure in the two countries during the previous 19-
year period. For China, we estimate the total economic burden, from 2012-2030, to be 27.8 
trillion (in 2010 USD). This figure swamps the total health expenditure in China during the 
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previous 19 years, which was approximately USD 2.2 trillion. For India, the corresponding 
figures are USD 6.2 trillion and USD 710 billion.
11
 
In economic terms, the savings from reducing the incidence of NCDs could be substantial. 
Bloom et al. (2011c) find that implementation of these “best buy” interventions for reducing 
NCDs in low- and middle-income countries (LMICs) could lead to a 10-15 percent reduction in 
premature death from NCDs (and in their economic costs). Using as an example a 12.5 percent 
reduction in mortality from ischemic heart disease and stroke in LMICs, Bloom et al. (2011c) 
find that economic savings would be USD 25 billion per year over the period 2011-2025. If the 
same 12.5 percent reduction in mortality (and costs) is assumed for all four disease categories 
covered in the report (diabetes, cardiovascular disease, respiratory diseases, and cancer), the 
annual savings would equal roughly USD 50 billion. 
The same reasoning can be extended to China and India. Applying the 12.5 percent reduction 
assumption used in the report, China could expect to decrease its economic losses from 
cardiovascular disease over the period 2012-2030 by USD 1.03 trillion, or USD 54 billion per 
year. If the same calculation is applied to all of the NCD categories (with the exception of mental 
health, because the “best buys” do not address mental health), the reduction in losses would be 
USD 2.3 trillion in total, or 121 billion per year. For India, cardiovascular disease savings would 
be USD 15 billion per year, and total savings would be USD 25 billion per year. For China, the 
cost of implementing these best buys is approximately USD 4 billion per year; the corresponding 
cost for India is USD 1.7 billion. (The cost data are from Bloom et al., 2011c.) For both 
countries, these rough estimates of benefit-cost ratios are extremely favorable and well in excess 
of 10.
12
 Thus, WHO’s best buys are expensive to implement, but more expensive not to 
implement. 
6. Conclusion 
This paper summarizes the economic costs associated with NCDs in China and India over the 
period 2012-2030. Results are obtained using EPIC, which augments the standard Solow 
                                                          
11
Data on health expenditures are from the World Bank Development Indicators: 
http://data.worldbank.org/indicator. 
12
 If we used discounted figures, which would be required in a benefit-cost analysis, the benefit-cost ratios would be 
lower, by roughly 66%. 
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economic growth model to incorporate health effects into national income via mortality effects 
on cohort size and the diversion of savings from productive capital formation into unproductive 
health care spending. Models of the economy are simulated in which we forecast future disease 
prevalence on the basis of current trends. This projection is then compared to a scenario in which 
disease prevalence is reduced to zero. Comparing the differences in output between these two 
scenarios allows for the estimation of the costs of a particular disease. Results are obtained for 
five domains, based on scaling from the WHO Global Burden of Disease database: 
cardiovascular diseases, cancers, chronic respiratory diseases, diabetes, and mental health. 
We find that the costs associated with NCDs in both China and India are substantial, both in 
absolute terms and relative to other indicators such as the flow of expenditure on health care in a 
given year in each country. For China, the cumulative cost associated with each of the five 
domains (cardiovascular disease, cancer, chronic respiratory disease, diabetes, and mental health) 
is USD 27.84 trillion; for India, the cumulative cost is USD 6.15 trillion (both figures in USD 
2010). The larger result for China reflects the facts that China has an older population and that in 
general losses are greater when GDP is higher. The most important NCD for each country is 
cardiovascular disease.  
The EPIC tool captures two very important channels by which mortality in general and non-
communicable diseases in particular can affect the economic performance of a country. The first 
channel is represented by the adverse effect of treatment costs on savings and thereby on capital 
accumulation, while the second channel is represented by the impact of disease-specific 
mortality on the effective labor force of a country. Since understanding both the development of 
the workforce and the evolution of the capital stock of a country are crucial to assessing its 
medium- and long-run economic performance, the current framework represents a step toward a 
more economically founded assessment of the macroeconomic impact of diseases than the 
standard cost-of-illness approach or the VSL approach. 
Nevertheless, we acknowledge that there is room for further improvements and refinements. For 
the sake of tractability we abstracted from more complex models of the economy, and other 
important channels by which diseases can exert their influence. To mention only the most 
important ones: diseases can affect schooling attendance and performance and thereby human 
capital accumulation, which is itself an important driving force of economic growth (cf. Lucas 
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1988, Mankiw et al., 1993); diseases can also hamper the ability of an economy to benefit from 
international knowledge spillovers (cf. Parente & Prescott, 1994); furthermore, a fraction of the 
treatment costs of illnesses might be financed by the government via distortionary taxation. In 
addition, by focusing on total NCD prevalence, the model estimates how much economic benefit 
could be derived from completely eliminating the diseases. In reality, the gradual nature of NCD 
development and the difficulty in reversing long-term trends in risk factors, among other things, 
put a limit on how much of the economic impact can be avoided. Thus the magnitude of the 
impact estimated through the model should be considered only indicative. More appropriate 
estimates to guide policy decisions, probably based on measures of avertable incidence, need to 
be developed. 
An additional limitation of the model is that, in addition to mortality, it does not explicitly 
address the impact of NCDs on morbidity. Currently, the model simply assumes that sick 
individuals either do not work or die instantaneously; there is no spectrum of productivity 
associated with the severity or type of illness. A possible solution might involve the use of 
disability weights as a way to control for NCDs’ productivity impact on labor supply (Weil, 
2010). A related issue is whether the relative financial cost of an illness in a particular category 
(e.g., cancer) can be accurately captured using the DALY weights. For example, if breast cancer 
represents 10 percent of the total DALYs associated with cancer, we assume that it represents 10 
percent of total cancer costs. This is potentially problematic, but is necessary as we currently 
only have cost of treatment information for a limited number of conditions. Obtaining more 
comprehensive data on health care costs should be a priority for future research. Extending the 
model to allow examination of the distribution of NCD costs would also be useful.  
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Appendix 
Tables A-1 and A-2 provide a preliminary alternate scaling of the EPIC Output for 2012-2030 
based on the new GBD 2010 data. Country-level data are not yet available,
13
 so the values for 
East Asia and South Asia are used to construct the scaling factors from the output of the EPIC 
model to the overall burden of WHO NCD domains. It is apparent from Tables A-1 and A-2 that 
the conclusion that NCDs will impose a sizable economic burden on both China and India 
remains robust to this change in data source. One potentially notable difference is the larger 
burden of cancer for China in this estimate, which likely reflects the fact that breast cancer (the 
EPIC measurement that was scaled up) is a smaller proportion of total cancer in East Asia due to 
the high prevalence of smoking in comparison to all upper-middle-income countries. A larger 
difference worth noting is that the GBD 2010 data yield a substantially lower estimated burden 
for mental health, which likely reflects changes in GBD measurement and weighting rather than 
changes in the actual burden of mental illness. 
                                                          
13
 Country-level GBD 2010 data will be made available in September 2013 
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Table A-1. Scaling of EPIC Output for 2012-2030 
to Match Five WHO NCD Domains for China 
GBD 2010 
(trillions of 2010 USD) 
WHO 
Disease EPIC Disease 
EPIC 
Raw 
Output 
Disease Scaling 
Factor 
Scaled 
Raw 
Output 
Diabetes Diabetes 0.49 Diabetes/1.00 0.49 
Heart 
disease 
  (IHD+CBD)/0.82 7.63 
 Ischemic Heart 
Disease 
1.63   
 Cerebrovascular 
Disease 
4.66   
Respiratory 
disease 
COPD 4.03 COPD/0.84 4.81 
Cancer   Breast 
cancer/0.034 
5.51 
 Breast cancer 0.19   
Total 
physical 
   18.43 
Mental 
health 
  Total physical * 
0.24 
4.49 
Overall 
total 
   22.92 
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Table A-2. Scaling of EPIC Output for 2012-2030 
to Match Five WHO NCD Domains for India 
GBD 2010 
(trillions of 2010 USD) 
WHO 
Disease EPIC Disease 
EPIC 
Raw 
Output 
Disease Scaling 
Factor 
Scaled 
Raw 
Output 
Diabetes Diabetes 0.15 Diabetes/1.00 0.15 
Heart 
disease 
  (IHD+CBD)/0.77 2.22 
 Ischemic Heart 
Disease 
1.21   
 Cerebrovascular 
Disease 
0.49   
Respiratory 
disease 
COPD 0.71 COPD/0.70 1.01 
Cancer   Breast 
cancer/0.08 
0.25 
 Breast cancer 0.02   
Total 
physical 
   3.62 
Mental 
health 
  Total physical * 
0.32 
1.15 
Overall 
total 
   4.77 
 
 
 
 
 
